Les Produits Chimiques B.G.R., Inc.
Letter data
- Company
- Les Produits Chimiques B.G.R., Inc.
- Recipient
- Ms. Nathalie A. Bélanger | Vice-President and Owner | Les Produits Chimiques B.G.R., Inc. | 600 Avenue Delmar | Pointe-Claire | QC | H9R 4A8 | Canada
- Issue date
- 2020-05-21
- Posted date
- Not available
- FDA office
- Division of Drug Quality II
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 542247
- Reference number
- 320-18-64
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Les Produits Chimiques B.G.R., Inc.
MARCS-CMS 542247 —
May 21, 2020
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Reference #:
320-18-64
Product:
Drugs
Recipient:
Recipient Name
Ms. Nathalie A. Bélanger
Recipient Title
Vice-President and Owner
Les Produits Chimiques B.G.R., Inc.
600 Avenue Delmar
Pointe-Claire
QC
H9R 4A8
Canada
Issuing Office:
Division of Drug Quality II
United States
Dear Ms. Bélanger:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-18-64 dated July 23, 2018.
Based on our evaluation, it appears that you have adequately addressed the deviations contained in this warning letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.
The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Bill Fowler
Compliance Officer
Division of Drug Quality II
Content current as of:
05/21/2020
Regulated Product(s)
Drugs